Below are the most recent publications written about "Stomach Neoplasms" by people in Profiles.
-
Cruz-Correa M, Oh DY, Kato K, Tabernero J, Bai Y, Shi J, Lee KW, Hirano H, Spigel D, Wyrwicz L, Pazo Cid R, Cubillo Graci?n A, Xu Y, Sheng T, Yang S, Xu RH, Moehler M. Tislelizumab?+?Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up. Adv Ther. 2026 Jan; 43(1):165-183.
-
Singh A, Gupta I, Saha P, Hole A, Anthony F, Natu A, Smoot DT, Ashktorab H, Chilakapati MK, Gupta S. Raman spectroscopy for detecting gastric and liver cancer cells that entered a tolerant persistence state to survive cisplatin chemotherapy. Biochem Biophys Res Commun. 2025 11 19; 790:152891.
-
Singh A, Natu A, Anthony F, Muthu H, Khade B, Smoot DT, Ashktorab H, Gupta S. The synergistic action of HDAC inhibitor with cisplatin impedes survival and proliferation of drug-tolerant persister in gastric and liver cancer cells. Clin Epigenetics. 2025 Oct 08; 17(1):168.
-
Xiao S, Peng Y, Peng L, Xie X, Qin J, Ma H, Kang X, Bing C, Huang B, Liang K, Zhao Y, Rong X, Feng X, Fan X, Ashktorab H, Zhang Z, Jin Z, Zhang X. The novel protein SEMA3C-319aa triggers glutathione metabolism-dependent ferroptosis in gastric cancer. Oncogene. 2025 Oct; 44(39):3679-3693.
-
Du K, Zhang X, Qin Y, Ma H, Bing C, Deng S, Chen Y, Qin J, Chang S, Xiao S, Peng L, Xie X, Feng X, Fu X, Wei Y, Fan X, Ashktorab H, Smoot D, Jin Z, Peng Y. MAP3K13-232aa encoded by circMAP3K13 enhances cisplatin-induced pyroptosis by directly binding to IKKa in gastric adenocarcinoma. Cell Death Dis. 2025 Sep 01; 16(1):667.
-
Montes-Rodr?guez IM, Centeno-Girona H, P?rez-M?rtir SV, Rivera N, Cruz-Correa M. Actionable Genes and Carcinogenic Pathways for Gastric Cancer in Latinos. Cancer Med. 2025 Sep; 14(17):e71216.
-
Chang S, Fu X, Xiang L, Yuan Y, Xiao S, Peng L, Xie X, Kang X, Feng X, Ashktorab H, Peng Y, Jin Z, Zhang X. A novel protein encoded by circTUBGCP3 blocks ferroptosis and promotes gastric cancer progression. J Biol Chem. 2025 09; 301(9):110507.
-
Pal A, Bawali P, Brahma A, Rana SR, Mohapatra R, Chakraborty D, Poirah I, Samal S, Banerjee S, Smoot DT, Ashktorab H, Bhattacharyya A. RHOA-dependent regulation of mitochondrial remodeling and cell motility in hypoxia-exposed gastric epithelial cells. J Cell Sci. 2025 Jul 15; 138(14).
-
Cruz-Correa M, Xu RH, Moehler M, Oh DY, Kato K, Spigel D, Arkenau HT, Tabernero J, Zimina AV, Bai Y, Shi J, Lee KW, Hirano H, Wyrwicz L, Cid RP, Xu H, Sheng T, Barnes G. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study. Curr Med Res Opin. 2025 Jun; 41(6):1007-1016.
-
Zhou N, Yuan Y, Lin H, Wang J, Lin H, Ashktorab H, Smoot D, Jin Z, Zhuang S, Qin Y. Epigallocatechin Gallate Induces miR-192/215 Suppression of EGR1 in Gastric Cancer. Anticancer Res. 2025 May; 45(5):1935-1951.